Abstract
Introduction: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. Areas covered: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases acute coronary syndromes and chronic atrial fibrillation in patients with hemophilia A and B. Expert opinion: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 505-510 |
| Number of pages | 6 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 13 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Mar 2012 |
Fingerprint
Keywords
- Acute coronary syndromes
- Anticoagulant therapy
- Antiplatelet therapy
- Atrial fibrillation
- Hemophilia A
- Hemophilia B
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia. / Mannucci, Pier Mannuccio.
In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 4, 03.2012, p. 505-510.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia
AU - Mannucci, Pier Mannuccio
PY - 2012/3
Y1 - 2012/3
N2 - Introduction: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. Areas covered: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases acute coronary syndromes and chronic atrial fibrillation in patients with hemophilia A and B. Expert opinion: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.
AB - Introduction: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. Areas covered: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases acute coronary syndromes and chronic atrial fibrillation in patients with hemophilia A and B. Expert opinion: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.
KW - Acute coronary syndromes
KW - Anticoagulant therapy
KW - Antiplatelet therapy
KW - Atrial fibrillation
KW - Hemophilia A
KW - Hemophilia B
UR - http://www.scopus.com/inward/record.url?scp=84857245676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857245676&partnerID=8YFLogxK
U2 - 10.1517/14656566.2012.656591
DO - 10.1517/14656566.2012.656591
M3 - Article
C2 - 22332913
AN - SCOPUS:84857245676
VL - 13
SP - 505
EP - 510
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 4
ER -